Goki Suda

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7228241/publications.pdf

Version: 2024-02-01

65 papers	1,238 citations	361045 20 h-index	433756 31 g-index
66 all docs	66 docs citations	66 times ranked	1704 citing authors

#	Article	IF	Citations
1	Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma. Cancers, 2022, 14, 232.	1.7	6
2	Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. PLoS ONE, 2022, 17, e0261760.	1.1	17
3	Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. Journal of Gastroenterology, 2022, 57, 120-132.	2.3	20
4	Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication. Scientific Reports, 2022, 12, 1449.	1.6	9
5	The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease. Hepatology Research, 2022, 52, 508-521.	1.8	1
6	Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferonâ€lambda 3 induction in chronic hepatitis B patients. Hepatology Research, 2022, 52, 586-596.	1.8	4
7	Overestimated Renal Function in Patients with Liver Cirrhosis Predicts Poor Prognosis. Hepatology Research, 2022, , .	1.8	4
8	Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients. PLoS ONE, 2022, 17, e0270786.	1.1	1
9	Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1â€“3 signaling, but not FGFR4 signaling. Carcinogenesis, 2021, 42, 58-69.	1.3	21
10	Recent advances in the treatment of hepatitis C virus infection for special populations and remaining problems. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1152-1158.	1.4	13
11	Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. Journal of Gastroenterology, 2021, 56, 67-77.	2.3	34
12	Tenofovirâ€“disoproxilâ€“fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. Journal of Gastroenterology, 2021, 56, 168-180.	2.3	29
13	Changes in the estimated renal function after hepatitis C virus eradication with directâ€acting antiviral agents: Impact of changes in skeletal muscle mass. Journal of Viral Hepatitis, 2021, 28, 755-763.	1.0	6
14	Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma. PLoS ONE, 2021, 16, e0247728.	1.1	3
15	Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report. BMC Infectious Diseases, 2021, 21, 389.	1.3	1
16	Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C. Scientific Reports, 2021, 11, 9207.	1.6	8
17	Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia. Nutrients, 2021, 13, 2415.	1.7	8
18	Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. Hepatology Research, 2021, 51, 979-989.	1.8	20

#	Article	IF	Citations
19	Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI. Cancers, 2021, 13, 3633.	1.7	10
20	Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals. Scientific Reports, 2021, 11, 16616.	1.6	6
21	Genomic profiling of intestinal/mixedâ€type superficial nonâ€ampullary duodenal epithelial tumors. JGH Open, 2021, 5, 1071-1077.	0.7	2
22	Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy. World Journal of Gastrointestinal Oncology, 2021, 13, 2076-2087.	0.8	4
23	Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a realâ€world setting. JGH Open, 2020, 4, 54-60.	0.7	36
24	Timeâ€dependent changes in the seroprevalence of COVIDâ€19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVIDâ€19. Hepatology Research, 2020, 50, 1196-1200.	1.8	11
25	Computed tomography, not bioelectrical impedance analysis, is the proper method for evaluating changes in skeletal muscle mass in liver disease. JCSM Rapid Communications, 2020, 3, 103-114.	0.6	8
26	Durable response without recurrence to Tolvaptan improves long-term survival. Journal of Gastroenterology, 2020, 55, 1150-1161.	2.3	4
27	Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria. Hepatology Research, 2020, 50, 966-977.	1.8	35
28	Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapyâ€associated hepatitis in Japan. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1782-1788.	1.4	22
29	Analysis of the optimal psoas muscle mass index cutâ€off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people. Hepatology Research, 2020, 50, 715-725.	1.8	28
30	High serum angiopoietinâ€2 level predicts nonâ€regression of liver stiffness measurementâ€based liver fibrosis stage after directâ€acting antiviral therapy for hepatitis C. Hepatology Research, 2020, 50, 671-681.	1.8	20
31	Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis. Scientific Reports, 2020, 10, 321.	1.6	21
32	Baseline angiopoietinâ€2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. JGH Open, 2020, 4, 880-888.	0.7	13
33	Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection. Journal of Gastroenterology, 2019, 54, 78-86.	2.3	19
34	Nutrition is often ignored in management of chronic liver diseases. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1127-1128.	1.4	1
35	Entecavir treatment of hepatitis B virusâ€infected patients with severe renal impairment and those on hemodialysis. Hepatology Research, 2019, 49, 1294-1304.	1.8	32
36	Effects of resistanceâ€associated variants in genotype 2Âhepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs. Hepatology Research, 2019, 49, 1275-1285.	1.8	8

#	Article	IF	Citations
37	Quantifying Protein-Specific N-Glycome Profiles by Focused Protein and Immunoprecipitation Glycomics. Journal of Proteome Research, 2019, 18, 3133-3141.	1.8	12
38	The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment. Internal Medicine, 2019, 58, 943-947.	0.3	5
39	Comparative Glycomic Analysis of Sialyl Linkage Isomers by Sialic Acid Linkage-Specific Alkylamidation in Combination with Stable Isotope Labeling of Î±2,3-Linked Sialic Acid Residues. Analytical Chemistry, 2019, 91, 13343-13348.	3.2	12
40	Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter. Hepatology Research, 2019, 49, 1207-1217.	1.8	19
41	Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection. Journal of Gastroenterology, 2019, 54, 641-649.	2.3	21
42	Evaluation of clinical utility of PIVKA-II using a chemiluminescent immunoassay. Acta Hepatologica Japonica, 2019, 60, 397-404.	0.0	0
43	Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases. Internal Medicine, 2019, 58, 797-802.	0.3	4
44	Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction. Hepatology Research, 2018, 48, 529-538.	1.8	15
45	Treatment of hepatitis C in special populations. Journal of Gastroenterology, 2018, 53, 591-605.	2.3	26
46	Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. Journal of Gastroenterology, 2018, 53, 119-128.	2.3	49
47	Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study. Hepatology Research, 2018, 48, E146-E154.	1.8	1
48	Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. PLoS ONE, 2018, 13, e0209615.	1.1	29
49	Macrophage-Derived Extracellular Vesicles Induce Long-Lasting Immunity Against Hepatitis C Virus Which Is Blunted by Polyunsaturated Fatty Acids. Frontiers in Immunology, 2018, 9, 723.	2.2	56
50	Lâ€Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis. Hepatology Communications, 2018, 2, 910-922.	2.0	67
51	Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection. Journal of Hepatology, 2017, 67, 1106-1108.	1.8	21
52	A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma. Drugs in R and D, 2017, 17, 381-388.	1.1	12
53	Decreased RNA-binding motif 5 expression is associated with tumor progression in gastric cancer. Tumor Biology, 2017, 39, 101042831769454.	0.8	8
54	Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. Journal of Gastroenterology, 2017, 52, 1122-1129.	2.3	32

#	Article	IF	Citations
55	Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virusâ€infected patients with renal impairment. Hepatology Research, 2017, 47, 1127-1136.	1.8	31
56	Fibroblast growth factor-2â€“mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma. Carcinogenesis, 2017, 38, 1073-1083.	1.3	64
57	Hepatitis B virus X protein impairs Î±â€interferon signaling via upâ€regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A. Journal of Medical Virology, 2017, 89, 267-275.	2.5	29
58	Anti-adipogenic and antiviral effects of<scp>l</scp>-carnitine on hepatitis C virus infection. Journal of Medical Virology, 2017, 89, 857-866.	2.5	20
59	Combination of neutrophilâ€toâ€lymphocyte ratio and early desâ€Î³â€carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma. Hepatology Research, 2017, 47, 533-541.	1.8	13
60	Prevalence and characteristics of naturally occurring sofosbuvir resistanceâ€associated variants in patients with hepatitis C virus genotype 1b infection. Hepatology Research, 2016, 46, 1294-1303.	1.8	27
61	Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. Journal of Gastroenterology, 2016, 51, 733-740.	2.3	103
62	Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment. Journal of Clinical and Translational Hepatology, 2016, 4, 320-327.	0.7	18
63	A pivotal role of KrÃ¼ppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma. Cancer Biology and Therapy, 2015, 16, 1453-1461.	1.5	22
64	Serum granulysin levels as a predictor of serious telaprevirâ€induced dermatological reactions. Hepatology Research, 2015, 45, 837-845.	1.8	15
65	IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones. Virology, 2010, 407, 80-90.	1.1	22